Biogen Appoints Michel Vounatsos Executive Vice President, Chief Commercial Officer

Biogen (NASDAQ: BIIB) today announced the appointment of Michel Vounatsos as executive vice president and chief commercial officer, effective April 18, 2016.

Mr. Vounatsos will oversee the development and execution of Biogen’s global commercial strategy, with a focus on the continued growth of Biogen’s product portfolio and the development of the commercial infrastructure and approach to support the company’s key pipeline assets. He will report to George Scangos, Ph.D., chief executive officer, and will be a member of the Biogen management team.

“Michel is a sophisticated global business leader who brings a track record of commercial success and creativity to Biogen,” said Dr. Scangos. “As the complexity of our business and the expectations of our stakeholders accelerate, Michel will play a critical role in driving our near-term growth while helping prepare our organization to support our increasingly robust and diverse pipeline.”

Mr. Vounatsos comes to Biogen after a 20 year career at Merck, where he most recently served as president, Primary Care Business Line and Merck Customer Centricity. Prior to this role, he held leadership positions at Merck across Europe and in China. Mr. Vounatsos attended the Universite Victor Segalen, Bordeaux II, in France, receiving his C.S.C.T. certificate in Medicine. He received his M.B.A. from the HEC School of Management in Paris.

“I am excited to work with my new colleagues to deliver on the unique promise of the Biogen pipeline as we seek to transform the lives of patients with neurodegenerative and rare diseases around the world,” said Mr. Vounatsos. “As I move to Biogen, I am grateful to the team at Merck for the tremendous opportunities I have had over the past two decades.”

About Biogen
Through cutting-edge science and medicine, Biogen discovers, develops and delivers worldwide innovative therapies for people living with serious neurological, autoimmune and rare diseases. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For more information, please visit www.biogen.com. Follow us on Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160330005257/en/

Contact information

Biogen
Media Contact:
Todd Cooper, +1-781-464-3260
public.affairs@biogen.com
or
Investor Contact:
Benjamin Strain, +1-781-464-2442
IR@biogen.com